A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY).

Autor: Geremia N; Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale 'Dell'Angelo', 30174, Venice, Italy; Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale Civile 'S.S. Giovanni e Paolo', 30122, Venice, Italy. Electronic address: nich.geremia@gmail.com., Sanson G; Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy., Principe L; Microbiology and Virology Unit, Great Metropolitan Hospital 'Bianchi-Melacrino-Morelli', 89128, Reggio Calabria, Italy. Electronic address: luigi.principe@gmail.com., Antonello RM; Department of Experimental and Clinical Medicine, University of Florence, 50121, Florence, Italy. Electronic address: rma.roby@gmail.com., Zerbato V; Infectious Diseases Unit, Trieste University Hospital, 34128, Trieste, Italy. Electronic address: verena.zerbato@gmail.com., Luzzati R; Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy. Electronic address: roberto.luzzati@asugi.sanita.fvg.it., Di Bella S; Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy. Electronic address: stefano932@gmail.com.
Jazyk: angličtina
Zdroj: Anaerobe [Anaerobe] 2024 Dec; Vol. 90, pp. 102901. Date of Electronic Publication: 2024 Aug 28.
DOI: 10.1016/j.anaerobe.2024.102901
Abstrakt: Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (26/120, 21.6 %), penicillin (11/71, 15.4 %) and metronidazole (14/131, 10.7 %). In conclusion, C. perfringens reduced susceptibility phenotype to first-line therapy.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: